OP029. Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix) | Zendy

AI Assistant Blog Pricing

OP029. Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.